Novo Nordisk: Semaglutide Heralds Commercial Dawn Of Obesity Market
Executive Summary
The Danish group expects its experimental GLP-1 semaglutide to prove so effective and safe in fighting obesity that it will spur commercial viability for medical treatment of the condition.